Eli Lilly (NYSE:LLY) Offers Better Than Expected Earning Guidance; Stock Hikes

Eli Lilly & Co’s (NYSE:LLY) stock hiked by almost 4% on Friday after the pharmaceutical company offered a 2013 forecasts that expected better-than-anticipated earnings for the neat year.

The drug-making giant reported that it presently estimates full-year adjusted earnings in the range of $3.75 to $3.90 per share. FactSet survey by analysts forecasted earnings of $3.73 per share for the year.

The drug giant announced that even though the patent will finish on its anti-depressant Cymbalta in the Q4, the company projects overall revenue growth for the year, assisted by its lineup of other products.

Eli Lilly further reported that yearly sales should hit a range of $22.6 billion to $23.4 billion, again ahead of the FactSet forecasts of $22.4 billion.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose +0.26% to settle at $3.77, GlaxoSmithKline plc (ADR) (NYSE:GSK) moved up +0.64% to end at $44.26 while Sanofi SA (ADR) (NYSE:SNY) jumped +0.67% to finish at $48.03 on Friday.

Eli Lilly & Co. (NYSE:LLY) last session’s volume of 13.59 million shares was higher than its average volume of 6.37 million shares. The stock after opening at $51.06 hit high price of $51.90 and then closed at $51.56 by scoring +3.70%.

LLY generated revenue of $22.69 billion in the previous twelve months and earned $4.12 billion. The Company showed a positive 18.15% in the net profit margin as well as in its operating margin which remained at 23.96%. Company’s annual sales growth for the past five years was 9.13%.

The LLY’s past twelve months’ price to sales ratio was 2.64 and price to cash ratio remained 8.67. As far as the returns are concerned, LLY’s return on equity was recorded as 26.47% and return on investment increased 15.79% while its return on asset stayed at 12.23%.

The stock showed weekly upbeat performance of 5.29% which was maintained for the month at 4.75%. Likewise the positive performance for the quarter was recorded as 8.66% and for the year was 29.13% while the YTD performance remained at 4.54%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Main Post and tagged , , , , , , , , , , , . Bookmark the permalink.